Travel Insurance with Lupus UK 2026: Which Providers Cover SLE and Which to Avoid

Travel insurance with lupus is obtainable from UK specialist providers but screening outcome varies significantly based on disease activity, organ involvement and the stability of the condition at the time of application. Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that causes inflammation across multiple organ systems. For travel insurance underwriting, the assessment focuses on severity and the risk of a flare or complication requiring emergency medical treatment abroad.

How Lupus Is Screened

When declaring lupus to a UK specialist travel insurance provider, the questionnaire addresses several key variables. Current disease activity is the primary underwriting concern: lupus in remission or low activity carries a materially different risk profile from active or flaring disease. Recent flares requiring hospital admission within the previous twelve to twenty-four months are a significant negative factor. Organ involvement is critical: lupus nephritis (kidney), lupus carditis (heart) and neuropsychiatric lupus are all more complex to underwrite than skin or joint manifestations.

Current medication is assessed for each case. Hydroxychloroquine as a sole medication for well-controlled SLE with no organ involvement is likely to generate a loading rather than an exclusion from most major specialist providers. Immunosuppressant therapy including azathioprine, mycophenolate mofetil or cyclophosphamide signals more active disease and will generate a more conservative underwriting response, potentially requiring telephone screening. Biologic therapies such as belimumab indicate severe or refractory disease and require telephone screening from providers with the broadest acceptance capability.

A rheumatologist's letter confirming current disease status, organ function and absence of pending investigations substantially strengthens the declaration and subsequent screening outcome, even where not formally required by the provider.

Which Providers Cover Lupus

Staysure, Avanti, InsureandGo and JustTravelCover can all consider stable, well-controlled SLE through automated online screening. For mild to moderate lupus in remission with no recent hospital admissions and stable medication, these mainstream specialist providers are the appropriate first assessment. Premiums include a loading reflecting the individual risk profile based on answered screening questions.

GoodToGo and Freedom Insure are the recommended providers for travellers with more active lupus, recent flares, organ involvement or complex medication regimens. Both emphasise capability for complex and difficult-to-place profiles and use telephone screening that allows a more nuanced individual assessment than automated systems permit. For travellers with lupus nephritis or neuropsychiatric lupus, telephone screening from GoodToGo or Freedom Insure is the most appropriate route.

iAmInsured is the specialist of last resort for travellers with active lupus who have been declined by other providers. Its telephone-first model and focus on high-risk profiles make it the relevant option when standard and mainstream specialist screening has not produced acceptable terms. AllClear Travel Insurance, with its Lloyd's of London underwriting, is an additional option for travellers wanting the financial security of the Lloyd's central fund mechanism.

Lupus and Destination Choice

Destination matters for lupus travellers beyond insurance screening. UV exposure triggers lupus flares in many patients, making high-UV destinations such as tropical locations and peak-summer Mediterranean resorts potentially problematic for SLE management regardless of insurance cover. Rheumatology advice on sun protection and UV exposure management during travel should be sought before booking any sun-focused holiday. For US travel specifically, the emergency medical cover limit is highly relevant: a lupus flare requiring inpatient treatment in the United States, including potential renal or neurological management, can generate hospital costs exceeding £10,000 per day. The ABI recommendation of £5 million minimum for US travel is a floor not a ceiling for travellers with organ-threatening SLE.

What to Declare

Lupus and all related conditions, complications and medications must be declared at the screening stage. This includes all organ manifestations, all immunosuppressant or biologic medications, and any related conditions such as lupus nephritis, antiphospholipid syndrome or Raynaud's phenomenon that may have been separately diagnosed. Antiphospholipid syndrome must be declared separately as it represents a distinct cardiovascular risk factor with direct implications for long-haul flight underwriting. The Consumer Insurance (Disclosure and Representations) Act 2012 requires travellers to take reasonable care not to make a misrepresentation at the screening stage.

Practical Travel Preparation with Lupus

Before purchasing travel insurance and before travelling, lupus patients should obtain a current letter from their rheumatologist confirming diagnosis, current treatment, disease activity status and fitness to travel. This letter serves two purposes: supporting the insurance declaration and providing overseas medical teams with essential background if emergency treatment is required. A translated summary in the local language is advisable for non-English-speaking destinations. Emergency contact details for the UK rheumatology team and the insurance assistance line should be saved before departure. Sufficient medication for the full trip duration plus a safety margin, along with a prescription copy in English and the local language, is standard travel preparation for lupus patients.

UK Regulatory Framework for Travel Insurance

All UK travel insurance policies sold to UK residents are regulated by the Financial Conduct Authority under the Insurance Conduct of Business sourcebook, known as ICOBS. ICOBS sets out requirements for product disclosure, fair treatment of customers and the handling of claims and complaints. Any insurer or distributor that breaches ICOBS is subject to FCA enforcement action including financial penalties, public censure and in serious cases prohibition from regulated activities.

The Consumer Duty, which came into force on 31 July 2023 under Policy Statement PS22/9, adds a cross-cutting standard requiring all FCA-regulated firms to deliver good outcomes for retail customers. For travel insurance specifically, the Consumer Duty places obligations on insurers to ensure that products are accessible and fair for customers with characteristics of vulnerability. Older travellers and those with pre-existing medical conditions are explicitly identified in the FCA's guidance as groups that face systematic disadvantage in the standard insurance market and that require particular consideration under the Consumer Duty framework. The four outcome areas of the Consumer Duty are products and services, price and value, consumer understanding, and consumer support. Each area has specific application to the specialist pre-existing conditions travel insurance market.

The Consumer Insurance (Disclosure and Representations) Act 2012 governs the disclosure obligations of all UK travel insurance policyholders. Under this Act, policyholders must take reasonable care not to make a misrepresentation when answering an insurer's screening questions. A deliberate or reckless misrepresentation entitles the insurer to avoid the policy in full and deny all claims regardless of whether the specific claim relates to the undisclosed condition. An inadvertent misrepresentation results in a proportionate remedy: if the insurer would not have written the policy at all, it may avoid but must return the premium; if it would have written at a higher premium, it may reduce the claim proportionately to reflect the premium difference.

The Financial Ombudsman Service is the statutory alternative dispute resolution body for all UK travel insurance complaints. The FOS can award compensation of up to £430,000 per complaint and its decisions are binding on all FCA-regulated firms. Travellers who disagree with any claim decision from any FCA-regulated travel insurer have the right to refer their complaint to the FOS free of charge after the insurer has had eight weeks to respond to the formal complaint. The FOS publishes biannual complaint data covering complaint volumes and uphold rates for named firms, providing an independent public benchmark of claims handling quality across the travel insurance market that is not dependent on provider marketing claims.

The Association of British Insurers publishes guidance on travel insurance best practice, including recommended minimum emergency medical cover limits. The ABI recommends a minimum of £2 million for European travel and at least £5 million for long-haul destinations. For travel to the United States specifically, where private hospital costs can frequently exceed £10,000 per day before surgical intervention or repatriation costs, the ABI guidance points to higher limits of £10 million or more for extended stays. The ABI also notes that cancellation underinsurance is one of the most common causes of partial claim settlements in the travel insurance market, and recommends that travellers ensure their cancellation cover is sufficient to cover the full prepaid cost of their trip including flights, accommodation and pre-booked excursions.

The Global Health Insurance Card, the GHIC, replaced the European Health Insurance Card for UK travellers after the Brexit transition period ended on 31 December 2020. The GHIC provides access to state healthcare in participating European Economic Area countries on the same terms as local residents. It does not cover private treatment, emergency repatriation, trip cancellation, baggage loss, personal liability or any other component of a comprehensive travel insurance policy. The FCA and ABI both advise UK travellers to carry both a valid GHIC and a comprehensive travel insurance policy when travelling in Europe. The two instruments are complementary rather than interchangeable, and holding a GHIC does not reduce the need for travel insurance in any European destination.

Frequently Asked Questions

Can I get travel insurance with lupus in the UK?

Yes. All major UK specialist providers can consider lupus through individual medical screening. Stable, well-controlled lupus without organ involvement typically receives a loading. Active or complex lupus requires telephone screening from providers including GoodToGo and Freedom Insure.

Do I need to declare lupus for travel insurance?

Yes. Lupus and all related conditions, complications and medications must be declared. The Consumer Insurance (Disclosure and Representations) Act 2012 requires accurate disclosure. Deliberate non-declaration allows policy avoidance and claim denial.

Does antiphospholipid syndrome need to be declared separately from lupus?

Yes. APS is a distinct condition with its own underwriting implications, primarily increased clotting risk relevant to long-haul flights. It must be declared separately from the lupus declaration even if managed by the same rheumatologist.

Which travel insurer is best for lupus?

For stable lupus: Staysure, Avanti, JustTravelCover and InsureandGo are appropriate first assessments. For active or organ-involved lupus: GoodToGo and Freedom Insure. Declined elsewhere: iAmInsured.